

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,

Karachi

No.2/2/2003-F.Sec.

Dated: 14/02/2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 14/10/2006 TO BE PUBLISHED ON 15/02/2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1382/2006	<u>16-10-2006</u> Novartis AG, Basel, CH (Priority 17-10-05 GB)	“Organic Compounds”
1383/2006	Wyeth, USA (Priority 17-10-05 USA)	“ Diazepinoquinolines, synthesis thereof, and intermediates thereto”
1384/2006	<u>17-10-2006</u> Merck Frosst Canada Ltd. Canada (Priority 27-10-05 USA)	“ A 4-oxo-1-(3-substituted phenyl)-1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same”
1385/2006	Tanabe Seiyaku Co., Ltd. Japan (Priority 21-10-05 Japan)	“ A pyrazolo [1,5-a] pyrimidine compound”
1386/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 19-10-05 Germany)	“ Carbamoylbenzotriazole derivatives as inhibitors of lip ases and phospholip ases”
1387/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 19-10-05 Germany)	“ Triazolopyridine derivatives as inhibitors of lip ases and phospholip ases”
1388/2006	Reckitt Benckiser (UK) Limited, United Kingdom (Priority 18-10-05 British)	“ Spraying device”
1389/2006	Reckitt Benckiser (UK) Limited, United Kingdom (Priority 18-10-05 British)	“ Spraying device”
1390/2006	Reckitt Benckiser (UK) Limited, United Kingdom	“ Spraying device”

(Priority 18-10-05 British)

1391/2006	Reckitt Benckiser (Australia) PTY Limited, Australia (Priority 19-10-05 UK)	“ Chemical formulation supply unit for a vapour emanating device”
1392/2006	Marathan Oil Company, USA (Priority 19-10-05 USA)	“ Process for converting gaseous alkanes to olefins and liquid hydrocarbons”
1393/2006	<u>18-10-2006</u> Bayer HealthCare AG, Germany (Priority 21-10-05 Germany)	“ Dicarboxylic acid derivatives and their use”
1394/2006	Alza Corporation, USA (Priority 19-10-05 USA)	“ Enhanced efficacy benzisoxazole derivative dosage forms and methods”
1395/2006	Plexxikon, Inc, USA (Priority 08-9-04 USA) Divisional	“ A pharmaceutically acceptable salt of peroxisome proliferators-activated receptors active compound”
1396/2006	1. AstraZeneca AB, Sweden 2. Schering AG Germany (Priority 20-10-05 Sweden)	“ Chemical Compounds”
1397/2006	Daiichi Pharmaceutical Co., Ltd Japan (Priority 20-6-2001 Japan) Divisional	“ A diamine compound as inhibitor of active ated blood coagulation factor X”
1398/2006	Daiichi Pharmaceutical Co., Ltd. Japan (Priority 20-6-01 Japan) Divisional	“ A salt or solvate of a diamine compound as inhibitor of actived blood coagulation factor X”
1399/2006	Merck & Co., Inc. USA	“ HIV Integrase inhibitors”
1400/2006	Honda Motor Co., Ltd	“ Internal combustion engine”

Japan
(Priority 02-11-05 Japan)

1401/2006	Wyeth, USA (Priority 12-02-01 USA) Divisional	“Novel succinate mixed salt of o-desmethyl-venlafaxine”
1402/2006	<u>19-10-2006</u> Avanir Pharmaceuticals, USA (Priority 14-02-03 USA) Divisional	“A salt of a cyano-substituted quinoline derivative as inhibitor of macrophage migration inhibitory factor”
1403/2006	Glaxo Group Limited, Great Britain (Priority 21-10-05 USA)	“Compounds”
1404/2006	Novartis AG, Switzerland (Priority 21-10-05 GB)	“Organic Molecules”
1405/2006	Janssen Pharmaceutica N.V., Belgium (Priority 26-10-05 Europe)	“Fast dissociating dopamine 2 receptor antagonists”
1406/2006	AstraZeneca AB, Sweden (Priority 28-10-05 USA)	“Chemical compounds”
1407/2006	Glaxo Group Limited, Great Britain (Priority 21-10-05 GB)	“Novel compounds”
1408/2006	Reckitt Benckiser (UK) Limited, UK (Priority 21-10-05 UK)	“Device”
1409/2006	Reckitt Benckiser (UK) Limited, UK (Priority 21-10-05 UK)	“Device”
1410/2006	Reckitt Benckiser (UK) Limited, UK	“Device”

(Priority 21-10-05 UK)


1411/2006	<u>20-10-2006</u> Eli Lilly and Company, USA (Priority 28-10-05 Europe)	“Kinase inhibitors”
1412/2006	Eli Lilly and Company, USA (Priority 28-10-05 Europe)	“Kinase inhibitors”
1413/2006	Noman Saeed, Islamabad, Pakistan	“The method of producing greater and continuous output force by using low input power”
1414/2006	SK Chemicals Co. Ltd., Republic of Korea (Priority 24-10-05 Korea)	“Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate”
1415/2006	<u>21-10-2006</u> Pfizer Products Inc., USA (Priority 27-10-05 USA)	“Histamine-3 receptor antagonists”
1416/2006	Wyeth, USA (Priority 24-10-05 USA)	“Method of protein production using anti-senescence compounds”
1417/2006	Bristol-Myers Squibb Co., USA (Priority 26-10-05 USA)	“Non-basic melanin concentrating hormone receptor-1 antagonists”
1418/2006	Maschinenfabrik Rieter AG, Switzerland (Priority 26-10-05 Germany)	“Drive for a modernized spinning or twisting machine”
1419/2006	Smithkline Beecham Corp., USA (Priority 26-10-05 USA)	“Substituted thiazoles and their use”
1420/2006	Novartis AG, Switzerland	“Modulators of chemokine receptor activity”

91/2005 Methanol Casale S.A.,
Switzerland “Pseudo-isothermal chemical reactor for
heterogeneous chemical reactions”

(Class: B01J, 18/02)

139223

Comprising a cylindrical shell having axis a reaction zone defined in said shell and at least one heat exchange unit, characterized in that at least one of said heat exchangers consist of a coil obtained from a single tubular element.



SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139135	1. Novartis AG, 2. University of Zurich, Switzerland	719/2004
139136	Wyeth Holdings Corporation, USA	736/2004
139137	Uster Technologies AG, Switzerland	746/2004
139138	Bioprogress Technology Limited, UK	751/2004
139139	Instituto Tecnológico Y De Estudios Superiores De Monterrey, Mexico	763/2004
139140	Bioprogress Technology Limited, UK	665/2006

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS & DESIGNS
TEL: 9215488